BriaCell Therapeutics Corp. 8-K

What Happened

• BriaCell Therapeutics Corp. announced it entered a Placement Agency Agreement with ThinkEquity LLC on May 31, 2026 and completed a best-efforts offering that closed on June 2, 2026. The company sold 1,449,300 common shares at $3.25 per share for gross proceeds of $4.71 million (before fees and expenses). Proceeds are intended for working capital, general corporate purposes, and to advance business objectives.

Key Details

• Shares sold: 1,449,300 common shares at $3.25 per share.
• Gross proceeds: $4.71 million (before placement agent fees and offering expenses).
• Placement agent: ThinkEquity LLC; compensation included a 7.5% cash fee of gross proceeds plus warrants to purchase 72,465 common shares.
• Placement Agent Warrants: exercisable upon issuance, expire 5 years from agreement date, exercise price $4.0625 per share; issued relying on Section 4(a)(2) exemption.
• Offering registration: Shares were offered under the Company’s Form S‑3 (File No. 333‑276650), declared effective Jan 31, 2024; prospectus supplement filed.
• Communications: Press releases announced pricing (May 31, 2026) and closing (June 2, 2026).

Why It Matters

• The transaction provides near-term liquidity of $4.71M to fund operations and corporate objectives.
• Placement agent warrants and the new shares represent potential future dilution if warrants are exercised; investors should monitor outstanding share count and any future exercises.
• Because the offering was made under the company’s effective S‑3 registration, shares were sold through a registered process, and the terms (fees and warrants) are disclosed in the 8‑K for investor review.